Mutual Termination Agreement dated February 14, 2024 by and among the Company, HDL Therapeutics, Inc. and IVCP Merger Sub, Inc

Termination. Pursuant to and in accordance with Section 10.1(d) of the Agreement, Acquiror and the Company hereby agree by mutual consent to terminate the Agreement effective as of the date hereof. Notwithstanding Section 10.3 of the Agreement, Section 11.5 of the Agreement shall not survive the termination of the Agreement.

No Reliance. Each Party acknowledges and agrees that in entering into this Termination Agreement, except as expressly set forth herein, it is not relying on any representations or warranties made by any Person (including any officers, directors, attorneys, representatives, employees, agents, and insurers of any Party) regarding this Termination Agreement or the implications hereof.

Further Cooperation to Effectuate This Termination Agreement. Each Party covenants and agrees that, without expanding their substantive obligations hereunder, it shall do all acts and execute and obtain all documents, to the full extent necessary or appropriate, to implement and enforce this Termination Agreement according to its terms.

Entity Level Power/Authorization. Each Party hereby represents and warrants that:

it has the entity level power and authority and the legal right to make, deliver and perform under this Termination Agreement, and has taken all necessary entity level actions to authorize execution, delivery and performance under this Termination Agreement;

this Termination Agreement has been duly executed and delivered on its behalf; and

this Termination Agreement constitutes its legal, valid and binding obligations, enforceable against it in accordance with its terms, except as such enforceability may be limited by Enforceability Exceptions.

Release of Claims.

Release and Discharge by the Company. In consideration of the terms and conditions set forth in this Termination Agreement, the Company, on behalf of itself and its Subsidiaries and Affiliates, hereby irrevocably, fully, finally and completely releases and forever discharges Acquiror, Merger Sub and each of their Affiliates (collectively, the “Swiftmerge Parties”), of and from any and all claims, rights, causes of action, liens, debts, liabilities, demands, agreements, damages or injuries of any nature or sort whether in law or in equity, and whether based on any federal law, state law, common law right of action or otherwise, whether known or unknown, liquidated or unliquidated, foreseen or unforeseen, matured or unmatured, accrued or not accrued, contingent or fixed, past, present, or future, that are based on, arise out of, incidental to, in connection with, or related in any way to, the

Release and Discharge by the Swiftmerge Parties. Subject to Section 7 of this Termination Agreement, in consideration of the terms and conditions set forth in this Termination Agreement, the Swiftmerge Parties each, hereby irrevocably, fully, finally, and completely release and forever discharge each of the Company and its Affiliates, of and from any and all Released Claims, from the beginning of time through the date hereof.

Waiver of Unknown Claims. The Parties understand and agree that this is a total and complete release by them of all claims against each other and expressly waive any benefit conferred upon the Parties by any statutory provision or common law regarding the waiver of unknown claims.

Governing Law; Waiver of Jury Trial; Assigns. Section 11.8 and Section 11.16 of the Agreement are hereby incorporated by reference into this Termination Agreement, mutatis mutandis. This Termination Agreement shall extend to, be binding upon, and inure to the benefit of the Parties and their respective successors, heirs and assigns.

Non-Disparagement. Each Party agrees that it shall not, and it shall cause its Affiliates to not, directly or indirectly, at any time, make any public or private statement (i) that is negative or disparages or criticizes any other Party or any of such other Party’s Affiliates or (ii) would reasonably be expected to impact the goodwill or reputation of any other Party or any of such other Party’s Affiliates, including, in each case, any public or private disparaging statement about any other Party or such other Party’s Affiliates or the businesses of such other Party or its Affiliates, the Transactions or the termination of the Merger Agreement, as applicable, except as required by applicable Law, regulation or stock exchange rule to which the relevant Party is subject, or by the order of any court of competent jurisdiction.

Confidentiality. Within five (5) Business Days of the date hereof, each Party shall return or destroy all Confidential Information (as defined in that certain Confidentiality Agreement, dated December 6, 2022, between Acquiror and the Company (the “Confidentiality Agreement”), subject to and in accordance with Section 6 of the Confidentiality Agreement. The Parties hereby expressly acknowledge and agree that the Confidentiality Agreement shall survive the execution of this Termination Agreement and the termination of the Agreement in accordance with its terms. The Parties hereby expressly acknowledge and agree that all information regarding any other Party obtained in furtherance of or in connection with the Transactions, including information obtained from current or prospective representatives, agents or potential financing sources, shall constitute Confidential Information for purposes of the Confidentiality Agreement.

Headings. The headings contained in this Termination Agreement are included for convenience of reference only and shall not affect in any way the meaning or interpretation of this Termination Agreement.

Counterparts. This Termination Agreement may be executed and delivered (including by facsimile or portable document format (pdf) transmission) in one or more counterparts, and by each Party in separate counterparts, each of which when executed shall be deemed to be an original but all of which taken together shall constitute one and the same agreement.

SWIFTMERGE ACQUISITION CORP.

By:

/s/ J. Sam Bremner

Name:

J. Sam Bremner

Title:

Chief Executive Officer

IVCP MERGER SUB, INC.

By:

/s/ J. Sam Bremner

Name:

J. Sam Bremner

Title:

Chief Executive Officer

HDL THERAPEUTICS, INC.

By:

/s/ Michael Matin

Name:

Michael Matin

Title:

Chief Executive Officer